SYRE

Spyre Therapeutics Inc

Apr 08 • 04:00PM ET

51.98

+0.78 1.52 %

Healthcare • Biotechnology • USA • NASD

Peers: AMGN GILD REGN VRTX BIIB MRNA BMY PFE LLY NVS

| Held by: VTI IWM XBI VXF IBB IWO SCHA VTWO IWN FYC

Index	RUT	P/E	-	EPS (ttm)	-2.08	Insider Own	18.14%	Shs Outstand	78.19M	Perf Week	3.05%
Market Cap	4.08B	Forward P/E	-	EPS next Y	-3.11	Insider Trans	-0.96%	Shs Float	64.30M	Perf Month	26.56%
Enterprise Value	3.48B	PEG	-	EPS next Q	-0.67	Inst Own	92.37%	Short Float	15.55%	Perf Quarter	71.38%
Income	-135.82M	P/S	-	EPS this Y	-46.45%	Inst Trans	28.68%	Short Ratio	13.42	Perf Half Y	211.82%
Sales	0.00M	P/B	7.27	EPS next Y	-7.17%	ROA	-19.59%	Short Interest	10.00M	Perf YTD	58.67%
Book/sh	7.15	P/C	5.40	EPS next 5Y	-19.01%	ROE	-22.03%	52W High	51.26 1.40%	Perf Year	340.51%
Cash/sh	9.63	P/FCF	-	EPS past 3/5Y	57.01% 44.61%	ROIC	-18.99%	52W Low	10.91 376.44%	Perf 3Y	701.85%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.79% 5.88%	Perf 5Y	-72.93%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	34.23%	Oper. Margin	-	ATR (14)	2.78	Perf 10Y	-82.66%
Dividend Ex-Date	-	Quick Ratio	13.25	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	68.45	Recom	1.07
Dividend Gr. 3/5Y	- -	Current Ratio	13.25	EPS Q/Q	12.65%	SMA20	14.69%	Beta	2.99	Target Price	64.36
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	27.67%	Rel Volume	1.41	Prev Close	51.20
Employees	102	LT Debt/Eq	0.00	Earnings	Feb 19 AMC	SMA200	94.09%	Avg Volume	744.91K	Price	51.98
IPO	Apr 07, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	1.30% -	Trades		Volume	1,042,894	Change	1.52%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-18-25	Initiated	Mizuho	Outperform	$53
Dec-17-25	Initiated	Citigroup	Buy	$64
Sep-26-25	Initiated	Deutsche Bank	Buy	$43
Apr-08-25	Initiated	Leerink Partners	Outperform	$45
Mar-18-25	Initiated	Wolfe Research	Outperform	$27
Sep-04-24	Initiated	Wedbush	Outperform	$45
Jul-16-24	Initiated	Evercore ISI	Outperform
May-02-24	Initiated	Robert W. Baird	Outperform	$50
Mar-01-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$12 → $35
Dec-20-23	Initiated	BTIG Research	Buy	$32
Dec-11-23	Initiated	Jefferies	Buy	$31
Dec-11-23	Initiated	Guggenheim	Buy	$44
May-04-20	Initiated	Piper Sandler	Overweight	$12
Mar-21-19	Initiated	JP Morgan	Overweight	$14
Sep-04-18	Downgrade	Wells Fargo	Outperform → Market Perform
Apr-24-18	Initiated	Evercore ISI	Outperform	$37
Mar-14-18	Reiterated	Needham	Buy	$8 → $12

Show Previous Ratings

Apr-03-26 04:01PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire)
Mar-16-26 08:00AM	Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026 (GlobeNewswire) +10.48%
Mar-06-26 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire)
Feb-24-26 04:05PM	Spyre Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Feb-19-26 04:17PM	Spyre Therapeutics: Q4 Earnings Snapshot (Associated Press Finance) +14.28%
04:02PM	Loading…
04:02PM	Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-18-26 08:00AM	Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach (GlobeNewswire)
Feb-16-26 12:23PM	Spyre Therapeutics (SYRE) Set POC Readout Priorities for 2026 (Insider Monkey)
Feb-06-26 04:01PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire) +6.62%
Jan-23-26 04:00PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire) -6.03%
Jan-15-26 11:35AM	Wall Street Bullish on Spyre Therapeutics, Inc. (SYRE) with Strong Buy Rating (Insider Monkey)
Jan-12-26 08:00AM	Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2 (GlobeNewswire) +7.15%
Jan-08-26 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire)
Dec-08-25 11:30AM	A Short Squeeze Could Send This Little-Known Biotech Stock Soaring (Barchart)
Dec-05-25 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire)
09:46AM	Loading…
Dec-01-25 09:46AM	Carvana initiated, Zscaler downgraded: Wall Street's top analyst calls (The Fly)
Nov-17-25 12:15PM	Spyre Therapeutics (SYRE) Announces Positive Results for Phase 1 Study of SPY003 (Insider Monkey)
Nov-07-25 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire)
Nov-04-25 04:54PM	Spyre Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
04:01PM	Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody (GlobeNewswire)
Oct-29-25 04:05PM	Spyre Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-24-25 08:00AM	Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025 (GlobeNewswire)
Oct-15-25 04:15PM	Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million (GlobeNewswire) +5.67%
Oct-13-25 09:07PM	Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock (GlobeNewswire) +11.02%
04:01PM	Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants (GlobeNewswire)
Oct-05-25 09:00AM	Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025 (GlobeNewswire)
Oct-03-25 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire)
Sep-24-25 08:35PM	Spyre Therapeutics Inc. (SYRE) Enrolls First Patient in Its Patient 2 SKYWAY Trial (Insider Monkey) +6.12% -8.18%
Sep-15-25 08:00AM	Spyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases (GlobeNewswire) -5.18%
04:17PM	Loading…
Aug-05-25 04:17PM	Spyre Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) -5.39%
04:02PM	Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-01-25 04:41PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire)
Jul-03-25 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire)
Jun-17-25 07:30AM	Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts (PR Newswire) -11.64%
Jun-16-25 04:05PM	Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025 (PR Newswire)
Jun-06-25 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
May-30-25 09:55AM	Wall Street Analysts Predict a 244.05% Upside in Spyre Therapeutics (SYRE): Here's What You Should Know (Zacks)
May-28-25 08:30AM	Spyre Therapeutics to Participate in Upcoming June Investor Conferences (PR Newswire)
May-13-25 09:55AM	How Much Upside is Left in Spyre Therapeutics (SYRE)? Wall Street Analysts Think 258.34% (Zacks)
May-08-25 04:05PM	Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire) +9.64%
May-05-25 08:00AM	Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001 (PR Newswire) -6.75%
May-02-25 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
Apr-04-25 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) -8.58%
Mar-27-25 04:05PM	Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody (PR Newswire)
Mar-07-25 04:40PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
Feb-27-25 04:05PM	Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (PR Newswire) +7.24%
Feb-25-25 08:00AM	Spyre Therapeutics to Participate in Upcoming March Investor Conferences (PR Newswire)
Feb-19-25 08:00AM	Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation (PR Newswire)
Feb-07-25 05:13PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) -5.07%
Jan-13-25 08:00AM	Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts (PR Newswire)
Jan-03-25 05:20PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
Dec-18-24 08:00AM	Spyre Therapeutics Added to the Nasdaq Biotechnology Index (PR Newswire) -8.31%
Dec-02-24 05:03PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
08:00AM	Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies (PR Newswire)
Nov-25-24 05:11PM	Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference (PR Newswire)
Nov-18-24 09:18PM	Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock (PR Newswire) -6.17%
04:14PM	Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants (PR Newswire)
Nov-12-24 07:30AM	Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-47 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential for Both Q3M & Q6M Maintenance Dosing (PR Newswire) -8.97%
Nov-11-24 04:05PM	Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-47 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024 (PR Newswire)
Nov-07-24 04:05PM	Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire) +5.00%
Nov-01-24 04:44PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
Oct-30-24 04:05PM	Spyre Therapeutics to Participate in Upcoming November Investor Conferences (PR Newswire)
Oct-14-24 08:00AM	Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations (PR Newswire) +6.83%
Oct-04-24 05:00PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) -5.66%
Oct-01-24 08:00AM	Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer (PR Newswire) -6.63%
Sep-10-24 04:47PM	Spyre Therapeutics to Participate in Upcoming Investor Conference (PR Newswire)
Aug-07-24 11:53PM	SYRE Stock Earnings: Spyre Therapeutics Beats EPS for Q2 2024 (InvestorPlace) -5.72%
04:05PM	Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Jul-18-24 08:00AM	NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors (GlobeNewswire) -5.22%
Jun-18-24 07:30AM	Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-47 Antibody, for the Treatment of Inflammatory Bowel Disease (PR Newswire)
Jun-03-24 05:23PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) +5.26% -7.31%
May-29-24 08:30AM	Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference (PR Newswire)
May-15-24 07:30AM	Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors (PR Newswire)
May-09-24 10:54PM	SYRE Stock Earnings: Spyre Therapeutics Misses EPS for Q1 2024 (InvestorPlace) +6.57%
04:02PM	Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
May-03-24 05:00PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
Apr-01-24 05:00PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) -7.27%
Mar-18-24 08:00AM	Spyre Therapeutics Announces $180 Million Private Placement (PR Newswire) -11.68%
Mar-04-24 08:50AM	Here's What Could Help Spyre Therapeutics (SYRE) Maintain Its Recent Price Strength (Zacks) +16.96%
Mar-01-24 05:25PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) +8.97%
Feb-29-24 04:05PM	Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (PR Newswire) +5.13%
Feb-26-24 07:30AM	Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference (PR Newswire)
Feb-08-24 07:30AM	Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation (PR Newswire)
Feb-06-24 09:55AM	Here's Why Spyre Therapeutics (SYRE) Could be Great Choice for a Bottom Fisher (Zacks)
Feb-05-24 07:30AM	Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors (PR Newswire)
Feb-02-24 05:30PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
Dec-22-23 05:00PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) +5.52% +6.22%
Dec-08-23 07:19AM	Spyre Therapeutics raises $180 million to advance anti-inflammatory drugs (BioPharma Dive)
Dec-07-23 06:20PM	Spyre Therapeutics Announces $180 Million Private Placement (PR Newswire)
Nov-28-23 08:00AM	Spyre Therapeutics to Present at Upcoming Investor Conference (PR Newswire) +20.73%
Nov-27-23 08:30AM	Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD (PR Newswire) +8.79%
Nov-22-23 05:00PM	Aeglea BioTherapeutics Announces Grants of Inducement Awards (PR Newswire) +6.26%
Nov-09-23 06:26PM	Aeglea: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Nov-03-23 05:00PM	Aeglea BioTherapeutics Announces Grants of Inducement Awards (PR Newswire) -5.39%
Oct-30-23 08:00PM	Aeglea BioTherapeutics to Participate in Upcoming November Investor Conferences (PR Newswire) +9.57%
Oct-02-23 06:02PM	Aeglea BioTherapeutics Announces Grants of Inducement Awards (PR Newswire)
Sep-14-23 05:03PM	Aeglea BioTherapeutics to Participate in Upcoming September Conference (PR Newswire) -6.63%
Sep-07-23 08:40AM	Aeglea BioTherapeutics Announces Reverse Stock Split (PR Newswire)

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Turtle Cameron	Chief Executive Officer	Apr 01 '26	Sale	49.33	15,000	739,912	627,540	Apr 03 09:30 PM
Sloan Sheldon	Chief Medical Officer	Apr 01 '26	Option Exercise	21.66	7,958	172,370	7,958	Apr 03 09:30 PM
Sloan Sheldon	Chief Medical Officer	Apr 01 '26	Sale	50.00	7,958	397,900	0	Apr 03 09:30 PM
Burrows Scott L	Chief Financial Officer	Apr 01 '26	Option Exercise	14.50	7,500	108,750	105,494	Apr 03 09:29 PM
Burrows Scott L	Chief Financial Officer	Apr 01 '26	Sale	49.34	7,500	370,076	97,994	Apr 03 09:29 PM
SHELDON SLOAN	Officer	Apr 01 '26	Proposed Sale	50.44	7,958	401,402		Apr 01 04:38 PM
Burrows Scott L	Chief Financial Officer	Mar 03 '26	Option Exercise	14.50	2,500	36,250	100,494	Mar 03 09:32 PM
Burrows Scott L	Chief Financial Officer	Mar 03 '26	Sale	40.65	2,500	101,620	97,994	Mar 03 09:32 PM
Turtle Cameron	Chief Executive Officer	Mar 02 '26	Sale	42.19	15,000	632,866	642,540	Mar 03 09:31 PM
SCOTT BURROWS	Officer	Mar 03 '26	Proposed Sale	42.49	10,000	424,900		Mar 03 04:43 PM
CAMERON TURTLE	Director	Mar 02 '26	Proposed Sale	43.01	60,000	2,580,600		Mar 02 04:31 PM
Turtle Cameron	Chief Executive Officer	Feb 02 '26	Sale	32.80	15,000	492,045	657,540	Feb 04 09:33 PM
Turtle Cameron	Chief Executive Officer	Jan 02 '26	Sale	30.68	15,000	460,134	671,907	Jan 06 09:36 PM
Turtle Cameron	Chief Executive Officer	Dec 01 '25	Sale	29.02	15,000	435,356	686,907	Dec 03 09:52 PM
Turtle Cameron	Chief Executive Officer	Nov 03 '25	Sale	23.33	45,000	1,049,778	701,907	Nov 05 09:15 PM
CAMERON TURTLE	Director	Nov 03 '25	Proposed Sale	24.46	90,000	2,201,400		Nov 03 04:24 PM
Burrows Scott L	Chief Financial Officer	Sep 02 '25	Sale	16.26	18,428	299,639	97,994	Sep 03 06:53 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SYRE

Spyre Therapeutics Inc

Upgrade your Finviz experience